These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10413641)

  • 21. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
    Tardiff BE; Califf RM; Tcheng JE; Lincoff AM; Sigmon KN; Harrington RA; Mahaffey KW; Ohman EM; Teirstein PS; Blankenship JC; Kitt MM; Topol EJ
    J Am Coll Cardiol; 1999 Jan; 33(1):88-96. PubMed ID: 9935014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
    Leonardi S; Thomas L; Neely ML; Tricoci P; Lopes RD; White HD; Armstrong PW; Giugliano RP; Antman EM; Califf RM; Newby LK; Mahaffey KW
    J Am Coll Cardiol; 2012 Dec; 60(22):2296-304. PubMed ID: 23122801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Occurrence of non-Q wave myocardial infarction following percutaneous coronary intervention in the stent era: systematic monitoring of the three markers of myocardial necrosis.
    Varani E; Balducelli M; Vecchi G; Gatti C; Lucchi GR; Maresta A
    J Interv Cardiol; 2005 Aug; 18(4):243-8. PubMed ID: 16115152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Troponin I elevation and cardiac events after percutaneous coronary intervention.
    Ricciardi MJ; Davidson CJ; Gubernikoff G; Beohar N; Eckman LJ; Parker MA; Bonow RO
    Am Heart J; 2003 Mar; 145(3):522-8. PubMed ID: 12660677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
    Tornvall P; Nilsson T; Lagerqvist B
    J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?
    Akkerhuis KM; Alexander JH; Tardiff BE; Boersma E; Harrington RA; Lincoff AM; Simoons ML
    Circulation; 2002 Feb; 105(5):554-6. PubMed ID: 11827918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abciximab and percutaneous coronary intervention: new indications. Medium-term benefit.
    Prescrire Int; 2000 Apr; 9(46):36-8. PubMed ID: 11503782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
    Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
    Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy.
    Ellis SG; Chew D; Chan A; Whitlow PL; Schneider JP; Topol EJ
    Circulation; 2002 Sep; 106(10):1205-10. PubMed ID: 12208794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure.
    Gruberg L; Mehran R; Waksman R; Dangas G; Fuchs S; Wu H; Kent KM; Pichard AD; Satler LF; Stone GW; Leon MB
    Am J Cardiol; 2001 Jun; 87(12):1356-60. PubMed ID: 11397353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic implication of creatine kinase elevation following elective coronary artery interventions.
    Kong TQ; Davidson CJ; Meyers SN; Tauke JT; Parker MA; Bonow RO
    JAMA; 1997 Feb; 277(6):461-6. PubMed ID: 9020269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT).
    Harrington RA; Lincoff AM; Califf RM; Holmes DR; Berdan LG; O'Hanesian MA; Keeler GP; Garratt KN; Ohman EM; Mark DB
    J Am Coll Cardiol; 1995 Jun; 25(7):1693-9. PubMed ID: 7759725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices.
    Kini A; Kini S; Marmur JD; Bertea T; Dangas G; Cocke TP; Sharma SK
    Catheter Cardiovasc Interv; 1999 Oct; 48(2):123-9. PubMed ID: 10506764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival.
    Sharma SK; Kini A; Marmur JD; Fuster V
    Circulation; 2000 Jul; 102(2):166-72. PubMed ID: 10889126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications.
    Adgey AA; Mathew TP; Harbinson MT
    Clin Cardiol; 1999 Apr; 22(4):257-65. PubMed ID: 10198735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Alexander JH; Sparapani RA; Mahaffey KW; Deckers JW; Newby LK; Ohman EM; Corbalán R; Chierchia SL; Boland JB; Simoons ML; Califf RM; Topol EJ; Harrington RA
    JAMA; 2000 Jan; 283(3):347-53. PubMed ID: 10647797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microvascular obstruction in acute coronary syndromes: onward to a new therapeutic target.
    Schwartz RS
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):170-2. PubMed ID: 16142803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.